Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant, covering 2021-12-21 to 2021-12-21. Get the full timeline:
Most recent: Clinical Trial Update: Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]